Clinical and Pre-Clinical Programs
CiVi 030 is an intravenous formulation of iloprost, a potent vasodilator and platelet inhibitor with anti-inflammatory and anti-fibrotic effects being developed for the treatment of digital ischemic episodes in people with Systemic Sclerosis (SSc).
CiVi 007 is a third generation PCSK9 antisense molecule being developed as an oral treatment for hypercholesterolemia and the prevention of atherosclerotic cardiovascular disease.
CiVi 020 is a potent, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist. PPARδ is a ligand activated transcription factor that exerts tissue specific control of genes involved in energy utilization.